Nektar Therapeutics (NKTR), Wednesday announced preclinical data on tumor necrosis factor receptor 2 or TNFR2 agonist and bivalent antibody NKTR-0165 for the treatment of inflammatory diseases.
According to the data, NKTR-0165 binds to TNFR2, a controller of inflammation, on regulatory T cells to boost immunosuppressive functions, the company stated.
Currently, Nektar's stock is climbing 0.79 percent, to $1.27 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.